Geneva, Switzerland and Boston, MA - 07 August, 2017 - ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that it will release Second Quarter financial results the afternoon of Tuesday, August 15, 2017. ObsEva management will host an investment community conference call at 5 p.m. Eastern Time (11 p.m. Central European Time) on August 15, 2017 to discuss the financial results and provide a corporate update.
Investors may participate by dialing (844) 419-1772 for U.S. callers and (213) 660-0921 for international callers, with conference ID: 56972196. Those interested in listening to the conference call live via the internet may do so by visiting the “Investors” page of the company’s website at www.obseva.com and clicking on the webcast link. A webcast replay will be available on the “Investors” page of ObsEva’s at www.obseva.com.
ObsEva will also be attending the Wedbush PacGrow Healthcare Conference taking place in New York, at Le Parker Meridien, on August 15-16, 2017. Company Management will be presenting on Wednesday August 16, 2017, at 2:30 p.m. Eastern Time.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol “OBSV”. For more information, please visit www.obseva.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s pipeline. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2016, and other filings ObsEva makes with the SEC from time to time. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
###
Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
+1 202-955-6222 x252
CEO Office Contact:
Delphine Renaud
delphine.renaud@obseva.ch
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/a3ac5db7-4401-4956-aaab-888df6c5f487
